Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Kilitch Drugs (India) Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 21, 2024, 9:55 pm

Market Cap 496 Cr.
Current Price 306
High / Low470/298
Stock P/E35.3
Book Value 118
Dividend Yield0.00 %
ROCE12.8 %
ROE7.83 %
Face Value 10.0
PEG Ratio0.46

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Kilitch Drugs (India) Ltd

Competitors of Kilitch Drugs (India) Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,465 Cr. 318390/10865.7 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 59.8 Cr. 80.694.9/25.822.9 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 85.5 Cr. 114155/87.012.8 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,221 Cr. 1,0801,335/62031.2 2072.08 %28.1 %21.1 % 2.00
Industry Average15,004.70N/A43.76N/AN/A16.2516.45N/A

All Competitor Stocks of Kilitch Drugs (India) Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales20.3319.9319.6223.5734.4336.6133.4530.7029.9745.4836.5641.2031.79
Expenses17.3119.6118.7119.9233.6631.5730.0326.7525.9939.2630.3832.5829.51
Operating Profit3.020.320.913.650.775.043.423.953.986.226.188.622.28
OPM %14.85%1.61%4.64%15.49%2.24%13.77%10.22%12.87%13.28%13.68%16.90%20.92%7.17%
Other Income0.371.511.050.171.310.380.970.240.691.020.560.492.96
Interest0.120.160.130.120.240.710.671.751.291.211.501.511.60
Depreciation0.500.500.440.700.201.130.820.890.930.910.710.820.81
Profit before tax2.771.171.393.001.643.582.901.552.455.124.536.782.83
Tax %21.30%40.17%47.48%14.00%62.80%36.03%40.00%-25.16%30.61%43.16%32.67%24.93%38.16%
Net Profit2.180.710.722.580.612.301.741.941.712.903.065.091.74
EPS in Rs1.430.460.761.390.721.861.341.561.522.282.162.951.81

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales14314610819212751825368114140155
Expenses1191249521252845755363104122132
Operating Profit232213-2-4-16705101823
OPM %16%15%12%-9%-19%-2%11%9%1%8%9%13%15%
Other Income00923213443335
Interest5430000111156
Depreciation665210102222243
Profit before tax131397-1-12-96925101219
Tax %22%20%22%70%4%5%16%55%48%27%35%31%
Net Profit101076-0-11-954146813
EPS in Rs7.757.9357.67-0.22-8.46-6.723.752.490.542.434.736.719.20
Dividend Payout %13%13%52%0%0%0%13%20%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2010-20112011-20122016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)0.00%660.00%18.18%155.56%-20.00%-75.00%300.00%50.00%33.33%
Change in YoY Net Profit Growth (%)0.00%660.00%-641.82%137.37%-175.56%-55.00%375.00%-250.00%-16.67%

Kilitch Drugs (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2010-2011 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:%
5 Years:13%
3 Years:31%
TTM:3%
Compounded Profit Growth
10 Years:%
5 Years:35%
3 Years:62%
TTM:13%
Stock Price CAGR
10 Years:26%
5 Years:21%
3 Years:26%
1 Year:-5%
Return on Equity
10 Years:%
5 Years:4%
3 Years:6%
Last Year:8%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 9:31 pm

MonthMar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital13131313131415151516161616
Reserves71101107958898106103112121131160173
Borrowings16900119131520223232
Other Liabilities535478111513126153513238
Total Liabilities153177127117113128144143203210220240259
Fixed Assets429942333332323065646263
CWIP430001320306534622
Investments01387249535653526071627276
Other Assets683046252635383047719010099
Total Assets153177127117113128144143203210220240259

Reserves and Borrowings Chart

Cash Flow

MonthMar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +22-29-81711044663-0
Cash from Investing Activity +-2441-31-20-2-4-14-10-38-158-10
Cash from Financing Activity +7-9-00-0617127-19
Net Cash Flow62-39-2-023-510-210-1

Free Cash Flow

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow23.006.004.00-2.00-4.00-2.005.00-2.00-13.00-10.00-10.00-4.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days975124328619614886109122132142149
Inventory Days62121241108439367035281018
Days Payable37191241541841083389525239200118
Cash Conversion Cycle1214424324196798989-367-79-4850
Working Capital Days19-11419723712410079108-1442554105
ROCE %15%8%-10%-9%5%6%1%3%6%10%13%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters68.33%68.25%68.25%68.25%68.24%68.24%68.24%68.24%69.23%69.23%69.23%69.23%
FIIs0.00%0.03%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public31.67%31.73%31.75%31.75%31.75%31.75%31.75%31.76%30.78%30.76%30.77%30.77%
No. of Shareholders8,7409,1299,1339,2099,3809,4359,5229,5739,0029,0629,5259,620

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)9.176.714.732.370.55
Diluted EPS (Rs.)9.176.714.732.370.55
Cash EPS (Rs.)10.527.595.573.711.84
Book Value[Excl.RevalReserv]/Share (Rs.)109.2396.6490.0383.5678.05
Book Value[Incl.RevalReserv]/Share (Rs.)109.2396.6490.0383.5678.05
Revenue From Operations / Share (Rs.)95.9989.5973.3144.2234.55
PBDIT / Share (Rs.)17.8013.158.525.072.80
PBIT / Share (Rs.)15.7210.876.943.791.50
PBT / Share (Rs.)12.037.716.173.301.04
Net Profit / Share (Rs.)8.445.323.992.430.54
NP After MI And SOA / Share (Rs.)9.086.714.732.370.54
PBDIT Margin (%)18.5414.6711.6211.478.10
PBIT Margin (%)16.3712.129.468.574.35
PBT Margin (%)12.538.608.417.473.01
Net Profit Margin (%)8.795.935.435.491.57
NP After MI And SOA Margin (%)9.457.486.445.351.57
Return on Networth / Equity (%)8.286.895.292.880.71
Return on Capital Employeed (%)14.3711.247.694.521.92
Return On Assets (%)6.084.753.511.800.58
Total Debt / Equity (X)0.170.140.140.110.10
Asset Turnover Ratio (%)0.670.650.480.410.38
Current Ratio (X)2.271.841.651.102.54
Quick Ratio (X)2.211.811.571.052.29
Inventory Turnover Ratio (X)26.2221.1614.048.317.10
Dividend Payout Ratio (NP) (%)0.000.000.000.00110.48
Dividend Payout Ratio (CP) (%)0.000.000.000.0032.74
Earning Retention Ratio (%)0.000.000.000.00-10.48
Cash Earning Retention Ratio (%)0.000.000.000.0067.26
Interest Coverage Ratio (X)4.834.1611.0810.426.04
Interest Coverage Ratio (Post Tax) (X)3.292.686.185.992.18
Enterprise Value (Cr.)638.35218.65272.89130.24137.43
EV / Net Operating Revenue (X)4.141.572.391.902.58
EV / EBITDA (X)22.2910.6720.5516.5731.80
MarketCap / Net Operating Revenue (X)4.061.562.291.832.35
Retention Ratios (%)0.000.000.000.00-10.48
Price / BV (X)3.561.431.880.981.06
Price / Net Operating Revenue (X)4.061.562.291.832.35
EarningsYield0.020.040.020.020.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Kilitch Drugs (India) Ltd as of November 22, 2024 is: 332.67

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 22, 2024, Kilitch Drugs (India) Ltd is Undervalued by 8.72% compared to the current share price 306.00

Intrinsic Value of Kilitch Drugs (India) Ltd as of November 22, 2024 is: 586.53

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 22, 2024, Kilitch Drugs (India) Ltd is Undervalued by 91.68% compared to the current share price 306.00

Last 5 Year EPS CAGR: 76.31%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (112.77 cr) compared to borrowings (13.08 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (86.69 cr) and profit (12.62 cr) over the years.
  1. The stock has a low average ROCE of 4.00%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 65.83, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 46.50, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kilitch Drugs (India) Ltd:
    1. Net Profit Margin: 8.79%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 14.37% (Industry Average ROCE: 16.25%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 8.28% (Industry Average ROE: 16.45%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 3.29
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.21
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 35.3 (Industry average Stock P/E: 43.76)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.17
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 105.16 Cr. and Equity Capital is Rs. 15.58 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsC-301/2, M.I.D.C., New Mumbai Maharashtra 400705info@kilitch.com
http://www.kilitch.com
Management
NamePosition Held
Mr. Mukund P MehtaManaging Director
Mr. Bhavin Mukund MehtaWhole Time Director
Mrs. Mira B MehtaWhole Time Director
Mr. Hemang J EngineerIndependent Director
Mr. Venkita Subramanian RajanIndependent Director
Prof. Vasudev Krishna MurtiIndependent Director

FAQ

What is the latest intrinsic value of Kilitch Drugs (India) Ltd?

The latest intrinsic value of Kilitch Drugs (India) Ltd as on 22 November 2024 is ₹332.67, which is 8.72% higher than the current market price of ₹306.00.

What is the Market Cap of Kilitch Drugs (India) Ltd?

The Market Cap of Kilitch Drugs (India) Ltd is 496 Cr..

What is the current Stock Price of Kilitch Drugs (India) Ltd as on 22 November 2024?

The current stock price of Kilitch Drugs (India) Ltd as on 22 November 2024 is ₹306.

What is the High / Low of Kilitch Drugs (India) Ltd stocks in FY 2024?

In FY 2024, the High / Low of Kilitch Drugs (India) Ltd stocks is 470/298.

What is the Stock P/E of Kilitch Drugs (India) Ltd?

The Stock P/E of Kilitch Drugs (India) Ltd is 35.3.

What is the Book Value of Kilitch Drugs (India) Ltd?

The Book Value of Kilitch Drugs (India) Ltd is 118.

What is the Dividend Yield of Kilitch Drugs (India) Ltd?

The Dividend Yield of Kilitch Drugs (India) Ltd is 0.00 %.

What is the ROCE of Kilitch Drugs (India) Ltd?

The ROCE of Kilitch Drugs (India) Ltd is 12.8 %.

What is the ROE of Kilitch Drugs (India) Ltd?

The ROE of Kilitch Drugs (India) Ltd is 7.83 %.

What is the Face Value of Kilitch Drugs (India) Ltd?

The Face Value of Kilitch Drugs (India) Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Kilitch Drugs (India) Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE